Pelabresib,Ruxolitinib
morphosys
['morphosys']
morphosys presents multiple analyses of the manifest phase 2 trial investigating the potential of pelabresib in the treatment of myelofibrosis at eha 2022 via john mascarenhas provides insights. 
Official account of The Tisch Cancer Institute @MountSinaiNYC. Committed to cancer prevention, detection, treatment & research. Appointments:  1-844-MD CANCER